Allergan, Inc.

Santen Pharmaceutical Co., Ltd.

Csl Behring Gmbh

Other

Unity Fertilizer LLC

David A Weber

Thierry Nivaggioli

Rahul Bhagat

Wendy M Blanda

Jane-Guo Shiah

Lin Peng

David Chou

Scott A Fowler

Paul I Cook

Scott M Kee

Robert Kling

James R Smith

Sreenivasu Mudumba

Philippe J M Dor

Sidiq Farooq

Robert L Lathrop

Ingrid Kane

Mike Rehal

Kenny Aptekarev

Mary E Gerritsen

Scott M Whitcup

Jeffrey Wayne Etter

David Maxwell Kleinman

W Dennis Moran

Roger E Tuttle

Scott J Gerondale

Jane Guo Shiah

Shawn R Davis

Sudeep Kaur Takhar

Sidiq Mohammed Farooq

Robert L Iii Lathrop

Philippe Jm Dor

Philippe J Dor

A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.

Methods of treatment using alpha-1-antitrypsin compositions

The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

Ocular implant made by a double extrusion process

A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Spearation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitabale for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.

A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Spearation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.

Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.

Formulations and methods for vascular permeability-related diseases or conditions

Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.

Rapamycin formulations and methods of their use

Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Liquid formulations for treatment of diseases or conditions

Convening dewatered heterogeneous sludge containing organic waste materials into a homogenous extract of carbon and amino acids for fertilizer production by adding sulfuric acid to the sludge; pumping the mixture through a blending mixer to mix the sludge with the sulfuric acid; adding conditioning chemicals to the mixture: pumping the mixture through a shearing mixer to mix the conditioning chemicals into the mixture; and mechanically agitating the mixture to create the homogenous extract. Optionally, the extract is pumped into a pipe reactor for reaction with an acid and a base to form a melt, which is rolled onto fertilizer particles to form accreted granules. The accreted granules are dried to form a granular fertilizer. Also described is an organically-enhanced granular nitrogen-phosphorous-sulfur fertilizer having at least about 0.5% by weight total carbon and amino acids, and accreted granule size greater than or equal to about 1.7 mm. The fertilizer is noncombustible.

Systems and methods for converting and processing organic sludges for multi-nutrient single accreted granule enhanced efficiency fertilizer production

A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Separation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.

Methods for treating and preventing ocular conditions by administering an compound to the vitreous chamber of a patient at risk of, or suffering from, the ocular condition.

Methods for treating retinopathy with extended therapeutic effect

Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Methods for treating and preventing retinopathic conditions by administering an anti-VEGF compound to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.

Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.

Growing community of inventors

Danville, CA, United States of America

David A Weber